Developing as a noteworthy advance in the battle against obesity, Retatrutide is attracting considerable attention . This treatment combines the action of two known GLP-1 binding agonists, semaglutide , with an new glucose-dependent hormonal component. Early study data have demonstrated significant fat decrease in patients with a high BMI , potent